Prolight has taken significant steps over the past year towards the commercialisation of its innovative POC platform, Psyros. The platform’s single-molecule counting technology enables early test results with laboratory-grade precision from the first patient examination, addressing a large and growing need for fast and accurate diagnostics near the patient— with high-sensitivity troponin as the initial application to rule in or rule out suspected myocardial infarction in patients presenting with acute chest pain.
In an ongoing pre-clinical validation study (the “Prevalidation Study”), the Company has demonstrated that the POC system delivers high analytical and clinical performance on plasma samples from biobanks. In parallel, Prolight has established industrial manufacturing capacity through a contract manufacturer and quality-assured processes — a critical foundation for future commercialisation. Before and during the Prevalidation Study, the Company achieved several key milestones:
In addition to the milestones already achieved, a study is currently underway using fresh whole blood from cardiac patients at St. Thomas’ Hospital in London — a crucial step in demonstrating the system’s performance with whole blood compared to plasma.
The results from the ongoing whole blood study using patient samples from St. Thomas’ Hospital are expected to be published before the end of Q2 2025 and represent a highly important milestone, as they could confirm the system’s performance on whole blood. Data confirming Psyros performance on whole blood has been requested by both the market and potential strategic partners. A positive outcome will be essential to advance toward a strategic partnership and enable completion of the full regulatory clinical performance study, which is expected to begin in the second half of 2025.
With the positive pre-clinical validation results, combined with the Rights Issue, the Company is establishing a stronger position toward potential partners and commercialisation. The Board of Directors has chosen to carry out the Rights Issue without securing underwriting commitments from external underwriters, as the Company believes there is strong shareholder support to meet the capital needs, several upcoming near-term milestones, and that the Rights Issue is considered a cost-effective financing solution.
Use of proceeds
Upon full subscription of the Rights Issue, the Company will receive gross proceeds of approximately SEK 100.3 million before issue costs. The total issue costs are estimated to amount to a maximum of approximately SEK 4.5 million. Based on the favorable initial results from the Prevalidation Study and the upcoming milestones over the next months, the Company intends to use the net proceeds from the Rights Issue for the following purposes:
Expected upcoming milestones
Results from the pre-clinical validation study on whole blood compared to plasma (Q2 2025)
The ongoing whole blood study at St. Thomas’ Hospital in London compares fresh whole blood from patients with plasma from cardiac patients. This study is critical as it may demonstrate the system’s performance on both whole blood and plasma in cardiac patients.
Finalisation of instrument development and initiation of instrument manufacturing (H2 2025)
Optimisation and finalisation of the high-sensitivity assay based on results and insights from the preclinical validation studies.
Final design and optimisation of the high-sensitivity troponin assay (H2 2025)
Following the analysis of whole blood data and final instrument design, the Company will freeze the assay, meaning no further changes can be made. This is a key milestone for proceeding with verification and validation processes and subsequently initiating the clinical performance study.
Final system verification (H2 2025)
A complete system verification will be carried out to confirm the platform’s robustness, user-friendliness, and reproducibility. This is an important milestone ahead of the clinical performance study and regulatory submission.
Conditions for a strategic partnership ahead of the clinical regulatory performance study (H2 2025)
Once the above milestones are met, the Company will be very well positioned for a potential strategic partnership. This would enable both additional financing and the execution of the clinical performance study in preparation for market approval and commercialisation in Europe.
Subscription period:
June 16, 2025 – June 30, 2025 (note that some trustees close subscriptions at an earlier date).
June 16, 2025 – June 25, 2025.
For each existing share held on the record date of June 12, 2025, one (1) subscription right is received, seven (7) subscription rights entitle to subscription of five (5) shares.
The subscription price in the rights issue amounts to SEK 0.20 per share.
If the Rights Issue is fully subscribed, the company can raise a maximum of approximately SEK 100.3 million before issue costs.
Important information
Due to legal restrictions, the information on this section of Prolight Diagnostics AB (publ)’s (the “Company”) website is not directed at or accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access this section of the website. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this section of the website.
The information contained in this section of the Company’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States, Australia, Japan, Canada, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any subscription rights, paid subscribed shares (Sw. Betalda tecknade aktier) or any shares or other securities of the Company (“Securities”) in the United States, Australia, Japan, Canada, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
No Securities have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“) or the securities legislation of any state or other jurisdiction of the United States, and thus, Securities may not be offered, subscribed for, exercised, pledged, sold, resold, granted, delivered or otherwise transferred, directly or indirectly, within or to the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the Securities is being made in the United States. The Securities have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan, Hong Kong, Singapore, or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold directly or indirectly, within or to Australia, Canada, Japan, Hong Kong, Singapore or any other jurisdiction in which it would be unlawful or would require registration or other measures.
No public offer of Securities is made in any country within the European Economic Area (“EEA”) other than Sweden. In other member states of the European Union (“EU”) or the United Kingdom, such an offer may only be made in accordance with the exemption in the regulation (EU) 2017/1129 (the “Prospectus Regulation”) or Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”). In other countries in the EEA that have implemented the Prospectus Regulation in their national legislation, such an offer may only be made in accordance with the exemption in the Prospectus Regulation and/or in accordance with each relevant implementing measure. This portion of the website is directed only at persons in countries within the EEA or in the United Kingdom who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation or the UK Prospectus Regulation. In other countries in the EEA that have not implemented the Prospectus Regulation in their national legislation, such an offer may only be made in accordance with the applicable exemption in national legislation.
With respect to the United Kingdom, information and documentation contained on this portion of the website is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”) or (iii) persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order or (iv) certified high net worth individuals and certified and self-certified sophisticated investors as described in Articles 48, 50, and 50A respectively of the Order or (v) persons to whom the information may otherwise be lawfully communicated (all such persons together being referred to as “relevant persons”). The information mentioned in any document on the website will only be available to and directed and distributed to relevant persons. Any person whom is not a relevant person should not act or rely on the documents or any of its contents.
Access to the information and documents contained on this section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the Company’s website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
I certify that:
1) I am resident outside and physically present outside of the United States, Australia, Canada, Japan, Hong Kong and Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction; and
2) I am resident and physically present (a) in Sweden or (b) outside of Sweden and each of the jurisdictions referred to in item (1) above and, in that case, I am authorised to access the information and documents on this website without being subject to any legal restriction and without any action required by the Company; and
3) I will not distribute or otherwise send any information contained on this section on the Company’s webpage to any person resident in, or physically present in, any of the jurisdictions referred to in item (1) above; and
4) I have read, understand and agree to comply with the restrictions set forth above.